English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/168563
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: Role of mitotic kinases

AutorOcaña, Alberto; Pérez-Peña, Javier; Alcaraz-Sanabria, Ana; Sánchez-Corrales, Verónica; Nieto-Jiménez, Cristina; Templeton, Arnoud J.; Seruga, Bostjan; Pandiella, Atanasio ; Amir, Eitan
Fecha de publicación2016
EditorImpact Journals
CitaciónOncotarget 7(16): 22865-22872 (2016)
Resumen[Introduction]: Accurate assessment of prognosis in early stage ovarian cancer is challenging resulting in suboptimal selection of patients for adjuvant therapy. The identification of predictive markers for cytotoxic chemotherapy is therefore highly desirable. Protein kinases are important components in oncogenic transformation and those relating to cell cycle and mitosis control may allow for identification of high-risk early stage ovarian tumors. [Methods]: Genes with differential expression in ovarian surface epithelia (OSE) and ovarian cancer epithelial cells (CEPIs) were identified from public datasets and analyzed with dChip software. Progression-free (PFS) and overall survival (OS) associated with these genes in stage I/II and late stage ovarian cancer was explored using the Kaplan Meier Plotter online tool. [Results]: Of 2925 transcripts associated with modified expression in CEPIs compared to OSE, 66 genes coded for upregulated protein kinases. Expression of 9 of these genes (CDC28, CHK1, NIMA, Aurora kinase A, Aurora kinase B, BUB1, BUB1βB, CDKN2A and TTK) was associated with worse PFS (HR:3.40, log rank p < 0.001). The combined analyses of CHK1, CDKN2A, AURKA, AURKB, TTK and NEK2 showed the highest magnitude of association with PFS (HR:4.62, log rank p < 0.001). Expression of AURKB predicted detrimental OS in stage I/II ovarian cancer better than all other combinations. [Conclusion]: Genes linked to cell cycle control are associated with worse outcome in early stage ovarian cancer. Incorporation of these biomarkers in clinical studies may help in the identification of patients at high risk of relapse for whom optimizing adjuvant therapeutic strategies is needed.
Versión del editorhttps://doi.org/10.18632/oncotarget.8118
Identificadoresdoi: 10.18632/oncotarget.8118
e-issn: 1949-2553
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
insilicokinase.pdf4,12 MBAdobe PDFVista previa
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.